Ocuphire Pharma
profile overview well tolerated oral dose up to day twice daily dosing progression of diabetic minimal ocular side effects ire cine | Ocuphire Pharma
Company
Deck Type
Deck date
May 2023
Slide
10 of 27
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
January 2023
product candidate profile for multiple retinal indications minor good patient compliance in zeta with mild | Ocuphire Pharma
Related slides by other companies
Kymera
Investor Presentation
November 2023
adverse events related to occurring in patient | Kymera
BenevolentAI
Investor Presentation
October 2022
ben indicative data from phase eczema area and severity index caveats phase was not powered to meaningfully assess only patients dosed with active per group maximum duration of dosing days score changes typically measured at days | BenevolentAI
Kymera
Investor Presentation
December 2023
adverse events related to occurring in patient | Kymera
Chimerix
Investor Presentation
August 2023
oral brain penetrant antagonist agonist second generation designed to expand to new indications efficacy in cell culture and central nervous system and other tumor models oral dose trials ongoing in cancers response reported by investigator in early dose cohort for a patient in recurrent non | Chimerix
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Results
January 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io